NASDAQ:GLYC GlycoMimetics (GLYC) Stock Price, News & Analysis $0.21 -0.01 (-2.29%) Closing price 04:00 PM EasternExtended Trading$0.20 -0.01 (-4.78%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About GlycoMimetics Stock (NASDAQ:GLYC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GlycoMimetics alerts:Sign Up Key Stats Today's Range$0.20▼$0.2250-Day Range$0.18▼$0.2752-Week Range$0.14▼$0.63Volume401,765 shsAverage Volume6.46 million shsMarket Capitalization$13.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewGlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Read More… GlycoMimetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreGLYC MarketRank™: GlycoMimetics scored higher than 33% of companies evaluated by MarketBeat, and ranked 707th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for GlycoMimetics.Read more about GlycoMimetics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for GlycoMimetics are expected to remain at ($0.08) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of GlycoMimetics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlycoMimetics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlycoMimetics has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about GlycoMimetics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.85% of the float of GlycoMimetics has been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in GlycoMimetics has recently decreased by 8.20%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlycoMimetics does not currently pay a dividend.Dividend GrowthGlycoMimetics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.55 Percentage of Shares Shorted2.85% of the float of GlycoMimetics has been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in GlycoMimetics has recently decreased by 8.20%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.94 News SentimentGlycoMimetics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for GlycoMimetics this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GlycoMimetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.70% of the stock of GlycoMimetics is held by insiders.Percentage Held by Institutions75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GlycoMimetics' insider trading history. Receive GLYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter. Email Address GLYC Stock News HeadlinesCrescent Biopharma to Present at the Jefferies Global Healthcare ConferenceMay 29 at 7:30 AM | globenewswire.comGLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYCMay 16, 2025 | businesswire.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.May 29, 2025 | Timothy Sykes (Ad)Crescent Biopharma Appoints David Lubner to Board of DirectorsApril 28, 2025 | globenewswire.comGlycoMimetics Stock Short Interest Report | NASDAQ:GLYC | BenzingaApril 18, 2025 | benzinga.comCrescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology TherapeuticsApril 3, 2025 | globenewswire.comCantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight RecommendationMarch 22, 2025 | msn.comCantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight RecommendationMarch 22, 2025 | msn.comSee More Headlines GLYC Stock Analysis - Frequently Asked Questions How have GLYC shares performed this year? GlycoMimetics' stock was trading at $0.2490 at the beginning of the year. Since then, GLYC shares have decreased by 14.4% and is now trading at $0.2132. View the best growth stocks for 2025 here. How were GlycoMimetics' earnings last quarter? GlycoMimetics, Inc. (NASDAQ:GLYC) announced its earnings results on Wednesday, May, 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. Who are GlycoMimetics' major shareholders? GlycoMimetics' top institutional shareholders include Wellington Management Group LLP (2.12%) and Jefferies Financial Group Inc. (0.91%). Insiders that own company stock include Public Equities LP Invus, Edwin Rock, Bruce S Johnson and Brian M Hahn. View institutional ownership trends. How do I buy shares of GlycoMimetics? Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GlycoMimetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Bristol-Myers Squibb (BMY), Meta Platforms (META), Advanced Micro Devices (AMD) and Alibaba Group (BABA). Company Calendar Last Earnings5/14/2025Today5/29/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLYC CIK1253689 Webwww.glycomimetics.com Phone(240) 243-1201Fax301-738-2137Employees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.88 million Net MarginsN/A Pretax Margin-397,340.00% Return on Equity-230.74% Return on Assets-177.39% Debt Debt-to-Equity RatioN/A Current Ratio1.92 Quick Ratio1.92 Sales & Book Value Annual Sales$10,000.00 Price / Sales1,375.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book2.67Miscellaneous Outstanding Shares64,532,000Free Float58,901,000Market Cap$13.76 million OptionableOptionable Beta1.70 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:GLYC) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.